Day One Biopharmaceuticals

dayonebio.com

Day One Biopharmaceuticals is a biotechnology company dedicated to developing targeted cancer therapies for patients of all ages, with a focus on pediatric patients. Their key product, OJEMDA™, is FDA-approved for treating relapsed or refractory pediatric low-grade glioma. The company differentiates itself by prioritizing rapid market access for therapies that address critical needs in cancer treatment, leveraging advances in research to benefit both children and adults. With a commitment to multistakeholder collaboration, Day One aims to improve outcomes for families facing cancer diagnoses, positioning itself as a leader in pediatric cancer drug development.